We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis Inc. (ZTS - Free Report) posted second-quarter 2018 adjusted earnings of 77 cents per share (excluding one-time items), which increased 45.3% year over year from 53 cents and beat the Zacks Consensus Estimate of 71 cents.
Total revenues rose 11.5% year over year (up 9% operationally excluding the impact of currency) to $1.42 billion in the quarter and beat the Zacks Consensus Estimate of $1.38 billion.
A look at Zoetis’ share price movement shows that the stock has outperformed the industry on a year-to-date basis. The stock has gained 23.6% against the industry’s decline of 0.1%.
Quarterly Highlights
Zoetis reports business results under two geographical operating segments — the United States and International. The company has a diverse portfolio of products for livestock and companion animals.
Revenues at the International segment grew 15% year over year (up 10% operationally) on a reported basis to $728 million. Livestock sales were up 10% on a reported basis (up 6% operationally) in the quarter despite a decline in Brazil as a result of a national trucking industry strike. Growth of cattle products was driven by favorable market conditions.
Moreover, sales of companion animal products grew 24% on a reported basis, reflecting higher sales of dermatology portfolio and two new parasiticide products, Simparica (sarolaner) for dogs and Stronghold Plus (selamectin/sarolaner) for cats.
Revenues from the United States segment increased 9% year over year to $677 million. Sales of companion animal products in this region were up 15%, primarily due to higher sales of dermatology portfolio and Simparica. This was partially offset by lower sales of some in-line products. Livestock revenues increased 1% mainly as growth in poultry and swine was offset by cattle.
2018 Outlook
Zoetis updated its outlook for 2018. The company expects adjusted earnings in the range of $3.00 to $3.10 per share revised from its previous expectation of $2.96-$3.10 per share.
Revenues are now expected in the range of $5.70 billion to $5.80 billionupdated from the previous guidance range of $5.675-$5.800 billion. The Zacks Consensus Estimate for earnings and revenues is pegged at $3.05 per share and $5.73 billion, respectively.
The updated guidance reflects the addition of Abaxis and changes in foreign exchange.
Other Updates
Zoetis completed the acquisition of Abaxis, Inc., a leading global provider of veterinary point-of-care diagnostic instruments for approximately $2 billion or $83 per share in cash. The deal is aimed to strengthen Zoetis’ presence in the animal health diagnostics market. This diagnostics category is a fast-growing portion of the animal health industry and has grown at a compound annual growth rate of approximately 10% over the last three years.
The company announced a five-year collaboration agreement with Regeneron Pharmaceuticals (REGN - Free Report) to develop monoclonal antibody (mAb) therapeutics. Per the terms, Regeneron has granted Zoetis a license for its proprietary VelocImmune antibody technology, which the latter will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals. In particular, Zoetis is exploring treatments for animals with allergic and immune-related conditions, pain, inflammatory disease and cancer.
Our Take
Zoetis’ second-quarter results exceeded both earnings and sales expectations on the back of growth from new parasiticide products (Simparicaand Stronghold Plus), vaccines and strong dermatology portfolio. The acquisition of Abaxis will further strengthen the company’s strong portfolio. We expect a strong performance in the second half as well.
Gilead’s earnings per share estimates have increased from $6.11 to $6.57 for 2018 and from $6.36 to $6.48 for 2019 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.43%. The stock has rallied 8.8% so far this year.
Vanda’s earnings per share estimates have increased from 18 cents to 20 cents for 2018 and from 77 cents to 80 cents for 2019 over the past 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 133.1%. The stock has rallied 35.9% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View
Zoetis Inc. (ZTS - Free Report) posted second-quarter 2018 adjusted earnings of 77 cents per share (excluding one-time items), which increased 45.3% year over year from 53 cents and beat the Zacks Consensus Estimate of 71 cents.
Total revenues rose 11.5% year over year (up 9% operationally excluding the impact of currency) to $1.42 billion in the quarter and beat the Zacks Consensus Estimate of $1.38 billion.
A look at Zoetis’ share price movement shows that the stock has outperformed the industry on a year-to-date basis. The stock has gained 23.6% against the industry’s decline of 0.1%.
Quarterly Highlights
Zoetis reports business results under two geographical operating segments — the United States and International. The company has a diverse portfolio of products for livestock and companion animals.
Revenues at the International segment grew 15% year over year (up 10% operationally) on a reported basis to $728 million. Livestock sales were up 10% on a reported basis (up 6% operationally) in the quarter despite a decline in Brazil as a result of a national trucking industry strike. Growth of cattle products was driven by favorable market conditions.
Moreover, sales of companion animal products grew 24% on a reported basis, reflecting higher sales of dermatology portfolio and two new parasiticide products, Simparica (sarolaner) for dogs and Stronghold Plus (selamectin/sarolaner) for cats.
Revenues from the United States segment increased 9% year over year to $677 million. Sales of companion animal products in this region were up 15%, primarily due to higher sales of dermatology portfolio and Simparica. This was partially offset by lower sales of some in-line products. Livestock revenues increased 1% mainly as growth in poultry and swine was offset by cattle.
2018 Outlook
Zoetis updated its outlook for 2018. The company expects adjusted earnings in the range of $3.00 to $3.10 per share revised from its previous expectation of $2.96-$3.10 per share.
Revenues are now expected in the range of $5.70 billion to $5.80 billionupdated from the previous guidance range of $5.675-$5.800 billion. The Zacks Consensus Estimate for earnings and revenues is pegged at $3.05 per share and $5.73 billion, respectively.
The updated guidance reflects the addition of Abaxis and changes in foreign exchange.
Other Updates
Zoetis completed the acquisition of Abaxis, Inc., a leading global provider of veterinary point-of-care diagnostic instruments for approximately $2 billion or $83 per share in cash. The deal is aimed to strengthen Zoetis’ presence in the animal health diagnostics market. This diagnostics category is a fast-growing portion of the animal health industry and has grown at a compound annual growth rate of approximately 10% over the last three years.
The company announced a five-year collaboration agreement with Regeneron Pharmaceuticals (REGN - Free Report) to develop monoclonal antibody (mAb) therapeutics. Per the terms, Regeneron has granted Zoetis a license for its proprietary VelocImmune antibody technology, which the latter will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals. In particular, Zoetis is exploring treatments for animals with allergic and immune-related conditions, pain, inflammatory disease and cancer.
Our Take
Zoetis’ second-quarter results exceeded both earnings and sales expectations on the back of growth from new parasiticide products (Simparicaand Stronghold Plus), vaccines and strong dermatology portfolio. The acquisition of Abaxis will further strengthen the company’s strong portfolio. We expect a strong performance in the second half as well.
Zoetis Inc. Price, Consensus and EPS Surprise
Zoetis Inc. Price, Consensus and EPS Surprise | Zoetis Inc. Quote
Zacks Rank & Other Stocks to Consider
Zoetis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth considering are Gilead Sciences Inc. (GILD - Free Report) and Vanda Pharmaceuticals Inc. (VNDA - Free Report) . Both of them carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead’s earnings per share estimates have increased from $6.11 to $6.57 for 2018 and from $6.36 to $6.48 for 2019 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.43%. The stock has rallied 8.8% so far this year.
Vanda’s earnings per share estimates have increased from 18 cents to 20 cents for 2018 and from 77 cents to 80 cents for 2019 over the past 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 133.1%. The stock has rallied 35.9% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>